Osteoporosis groups hide their synthetic vitamin D recommendations behind 40 dollar paywall

Created May 2015

The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) Endocrine Journal

Luisella Cianferotti, Claudio Cricelli, John A. Kanis, Ranuccio Nuti, Jean-Y. Reginster, Johann D. Ringe, Rene Rizzoli, Maria Luisa Brandi

Abstract

Several compounds are produced along the complex pathways of vitamin D3 metabolism, and synthetic analogs have been generated to improve kinetics and/or vitamin D receptor activation. These metabolites display different chemical properties with respect to the parental or native vitamin D3, i.e., cholecalciferol, which has been, so far, the supplement most employed in the treatment of vitamin D inadequacy. Hydrophilic properties of vitamin D3 derivatives facilitate their intestinal absorption and their manageability in the case of intoxication because of the shorter half-life. Calcidiol is a more hydrophilic compound than parental vitamin D3. Active vitamin D analogs, capable of binding the vitamin D receptor evoking vitamin D-related biological effects, are mandatorily employed in hypoparathyroidism and kidney failure with impaired 1α-hydroxylation. They have been shown to increase BMD, supposedly ameliorating calcium absorption and/or directly affecting bone cells, although their use in these conditions is jeopardized by the development of hypercalciuria and mild hypercalcemia. Further studies are needed to assess their overall safety and effectiveness in the long-term and new intermittent regimens, especially when combined with the most effective antifracture agents.

Big Pharma has made a huge investment in making a patentable synthetic form which is better than Vitamin D To my knowlege they have yet to be successful, yet many doctors prescribe the synthetic forms Overview Osteoporosis and vitamin D contains the following summary {include} Osteoporosis category includes the following {include} Comment: perhaps they worry about the drop in Osteo business in Austraiia -see below * 20X increase in vitamin D sold and 36 percent decrease in osteoporosis business in Australia – Nov 2013

But, references are free (none from 2015)

  1. Jones, G, Prosser, DE, Kaufmann, M ( 2014 ) Cytochrome P450-mediated metabolism of vitamin D. J. Lipid Res. 55: pp. 13

  2. Imawari, M, Akanuma, Y, Itakura, H, Muto, Y, Kosaka, K, Goodman, DS (1979) The effects of diseases of the liver on serum 25-hydroxyvitamin D and on the serum binding protein for vitamin D and its metabolites. J. Lab. Clin. Med. 93: pp. 171

  3. Zerwekh, JE (2008) Blood biomarkers of vitamin D status. Am. J. Clin. Nutr. 87: pp. 1087S-1091S

  4. Cianferotti, L, Marcocci, C (2012) Subclinical vitamin D deficiency. Best Pract. Res. Clin. Endocrinol. Metab. 26: pp. 523

  5. Binkley, N, Wiebe, D ( 2013 ) Clinical controversies in vitamin D: 25(OH)D measurement, target concentration, and supplementation. J. Clin. Densitom. 16: pp. 402

  6. Abboud, M, Puglisi, DA, Davies, BN, Rybchyn, M, Whitehead, NP, Brock, KE, Cole, L, Gordon-Thomson, C, Fraser, DR, Mason, RS ( 2013 ) Evidence for a specific uptake and retention mechanism for 25-hydroxyvitamin D (25OHD) in skeletal muscle cells. Endocrinology 154: pp. 3022

  7. Molnár, F, Sigüeiro, R, Sato, Y, Araujo, C, Schuster, I, Antony, P, Peluso, J, Muller, C, Mouriño, A, Moras, D, Rochel, N (2011) 1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor. Plos One 6: pp. e18124

  8. Holick, MF (2007) Vitamin D deficiency. N. Engl. J. Med. 357: pp. 266

  9. Girgis, CM, Clifton-Bligh, RJ, Hamrick, MW, Holick, MF, Gunton, JE ( 2013 ) The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr. Rev. 34: pp. 33

  10. Gerdhem, P, Ringsberg, KA, Obrant, KJ, Akesson, K (2005) Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos. Int. 16: pp. 1425

  11. Lai, JK, Lucas, RM, Clements, MS, Roddam, AW, Banks, E (2010) Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies. BMC Public Health. 10: pp. 331

  12. Pludowski, P, Holick, MF, Pilz, S, Wagner, CL, Hollis, BW, Grant, WB, Shoenfeld, Y, Lerchbaum, E, Llewellyn, DJ, Kienreich, K, Soni, M ( 2013 ) Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun. Rev. 12: pp. 976

  13. Bischoff-Ferrari, HA, Giovannucci, E, Willett, WC, Dietrich, T, Dawson-Hughes, B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84: pp. 18

  14. Wacker, M, Holick, MF ( 2013 ) Vitamin D—effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 5: pp. 111

  15. Hollis, BW, Wagner, CL ( 2013 ) Clinical review: the role of the parent compound vitamin D with respect to metabolism and function: Why clinical dose intervals can affect clinical outcomes. J. Clin. Endocrinol. Metab. 98: pp. 4619

  16. Chun, RF, Peercy, BE, Orwoll, ES, Nielson, CM, Adams, JS, Hewison, M ( 2014 ) Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 144: pp. 132

  17. Gallagher, JC, Sai, A, Templin, T, Smith, L (2012) Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann. Intern. Med. 156: pp. 425

  18. Dawson-Hughes, B, Mithal, A, Bonjour, JP, Boonen, S, Burckhardt, P, Fuleihan, GE, Josse, RG, Lips, P, Morales-Torres, J, Yoshimura, N (2010) IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 21: pp. 1151

  19. Holick, MF, Binkley, NC, Bischoff-Ferrari, HA, Gordon, CM, Hanley, DA, Heaney, RP, Murad, MH, Weaver, CM (2012) Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J. Clin. Endocrinol. Metab. 97: pp. 1153

  20. Rizzoli, R, Boonen, S, Brandi, ML, Bruyère, O, Cooper, C, Kanis, JA, Kaufman, JM, Ringe, JD, Weryha, G, Reginster, JY ( 2013 ) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr. Med. Res. Opin. 29: pp. 305

  21. Bischoff-Ferrari, HA, Willett, WC, Orav, EJ, Lips, P, Meunier, PJ, Lyons, RA, Flicker, L, Wark, J, Jackson, RD, Cauley, JA, Meyer, HE, Pfeifer, M, Sanders, KM, Stähelin, HB, Theiler, R, Dawson-Hughes, B (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 367: pp. 40

  22. Sanders, KM, Stuart, AL, Williamson, EJ, Simpson, JA, Kotowicz, MA, Young, D, Nicholson, GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303: pp. 1815

  23. Rossini, M, Adami, S, Viapiana, O, Fracassi, E, Idolazzi, L, Povino, MR, Gatti, D (2012) Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers. Calcif. Tissue Int. 91: pp. 365

  24. Haussler, MR, Jurutka, PW, Mizwicki, M, Norman, AW (2011) Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)2vitamin D3: genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 25: pp. 543

  25. Deluca, HF ( 2014 ) History of the discovery of vitamin D and its active metabolites. Bonekey Rep. 3: pp. 479

  26. Lund, J, DeLuca, HF (1966) Biologically active metabolite of vitamin D3 from bone, liver, and blood serum. J. Lipid Res. 7: pp. 739

  27. Avioli, LV, Lee, SW, McDonald, JE, Lund, J, DeLuca, HF (1967) Metabolism of vitamin D3-3H in human subjects: distribution in blood, bile, feces, and urine. J. Clin. Invest. 46: pp. 983

  28. Blunt, JW, DeLuca, HF, Schnoes, HK (1968) 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry 7: pp. 3317

  29. Blunt, JW, Tanaka, Y, DeLuca, HF (1968) Biological activity of 25-hydroxycholecalciferol, a metabolite of vitamin D3. Proc. Natl. Acad. Sci. USA 61: pp. 1503

  30. Blunt, JW, DeLuca, HF (1969) The synthesis of 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry 8: pp. 671

  31. Ponchon, G, Kennan, AL, DeLuca, HF (1969) “Activation” of vitamin D by the liver. J. Clin. Invest. 48: pp. 2032

  32. Fraser, DR, Kodicek, E (1970) Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 228: pp. 764

  33. Lawson, DE, Fraser, DR, Kodicek, E, Morris, HR, Williams, DH (1971) Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 230: pp. 228

  34. Boyle, IT, Miravet, L, Gray, RW, Holick, MF, Deluca, HF (1972) The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats. Endocrinology 90: pp. 605

  35. Holick, MF, Garabedian, M, DeLuca, HF (1972) 1,25-dihydroxycholecalciferol: metabolite of vitamin D3 active on bone in anephric rats. Science 176: pp. 1146

  36. Haddad, JG, Chyu, KJ (1971) Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J. Clin. Endocrinol. Metab. 33: pp. 992

  37. Belsey, R, Deluca, HF, Potts, JT (1971) Competitive binding assay for vitamin D and 25-OH vitamin D. J. Clin. Endocrinol. Metab. 33: pp. 554

  38. Holick, MF, Schnoes, HK, DeLuca, HF (1971) Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc. Natl. Acad. Sci. USA 68: pp. 803

  39. Norman, AW, Myrtle, JF, Midgett, RJ, Nowicki, HG, Williams, V, Popják, G (1971) 1,25-dihydroxycholecalciferol: identification of the proposed active form of vitamin D3 in the intestine. Science 173: pp. 51

  40. Tanaka, Y, DeLuca, HF, Omdahl, J, Holick, MF (1971) Mechanism of action of 1,25-dihydroxycholecalciferol on intestinal calcium transport. Proc. Natl. Acad. Sci USA 68: pp. 1286

  41. Frolik, CA, Deluca, HF (1971) 1,25-dihydroxycholecalciferol: the metabolite of vitamin D responsible for increased intestinal calcium transport. Arch. Biochem. Biophys. 147: pp. 143

  42. Garabedian, M, Holick, MF, Deluca, HF, Boyle, IT (1972) Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc. Natl. Acad. Sci. USA 69: pp. 1673

  43. Mawer, EB, Taylor, CM, Backhouse, J, Lumb, GA, Stanbury, SW (1973) Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet 1: pp. 626

  44. Chertow, BS, Baylink, DJ, Wergedal, JE, Su, MH, Norman, AW (1975) Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J. Clin. Invest. 56: pp. 668

  45. Frolik, CA, DeLuca, HF (1973) The stimulation of 1,25-dihydroxycholecalciferol metabolism in vitamin D-deficient rats by 1,25-dihydroxycholecalciferol treatment. J. Clin. Invest. 52: pp. 543

  46. Tanaka, Y, Deluca, HF (1971) Bone mineral mobilization activity of 1,25-dihydroxycholecalciferol, a metabolite of vitamin D. Arch. Biochem. Biophys. 146: pp. 574

  47. Raisz, LG, Trummel, CL, Holick, MF, DeLuca, HF (1972) 1,25-dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science 175: pp. 768

  48. Garabedian, M, Tanaka, Y, Holick, MF, Deluca, HF (1974) Response of intestinal calcium transport and bone calcium mobilization to 1,25-dihydroxyvitamin D3 in thyroparathyroidectomized rats. Endocrinology 94: pp. 1022

  49. Gray, RW, Caldas, AE, Wilz, DR, Lemann, J, Smith, GA, DeLuca, HF (1978) Metabolism and excretion of 3H-1,25-(OH)2-vitamin D3 in healthy adults. J. Clin. Endocrinol. Metab. 46: pp. 756

  50. Clemens, TL, Hendy, GN, Graham, RF, Baggiolini, EG, Uskokovic, MR, O’Riordan, JL (1978) A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin. Sci. Mol. Med. 54: pp. 329

  51. Diagnosis, prophylaxis and treatment of osteoporosis. Am. J. Med. 94: pp. 646

  52. Holick, MF, Semmler, EJ, Schnoes, HK, DeLuca, HF (1973) 1 -Hydroxy derivative of vitamin D 3: a highly potent analog of 1,25-dihydroxyvitamin D 3. Science 180: pp. 190

  53. Ueno, K, Okamiya, Y, Makita, T, Kurozumi, S, Kawashima, H, Hashimoto, Y (1979) Studies on biopharmacological activity of active vitamin D3 analogues (VII) Effect of 1 alpha-hydroxycholecalciferol on renal function in rats and Beagle dogs (Japanese). Nihon. Yakurigaku Zasshi. 75: pp. 617

  54. Morimoto, S, Imanaka, S, Koh, E, Shiraishi, T, Nabata, T, Kitano, S, Miyashita, Y, Nishii, Y, Ogihara, T (1989) Comparison of the inhibitions of proliferation of normal and psoriatic fibroblasts by 1 alpha,25-dihydroxyvitamin D3 and synthetic analogues of vitamin D3 with an oxygen atom in their side chain. Biochem. Int. 19: pp. 1143

  55. Tsurukami, H, Nakamura, T, Suzuki, K, Sato, K, Higuchi, Y, Nishii, Y (1994) A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif. Tissue Int. 54: pp. 142

  56. Tanaka, Y, Nakamura, T, Nishida, S, Suzuki, K, Takeda, S, Sato, K, Nishii, Y (1996) Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J. Bone Miner. Res. 11: pp. 325

  57. Uchiyama, Y, Higuchi, Y, Takeda, S, Masaki, T, Shira-Ishi, A, Sato, K, Kubodera, N, Ikeda, K, Ogata, E (2002) ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30: pp. 582

  58. Freitas, PH, Hasegawa, T, Takeda, S, Sasaki, M, Tabata, C, Oda, K, Li, M, Saito, H, Amizuka, N (2011) Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 49: pp. 335

  59. Harada, S, Mizoguchi, T, Kobayashi, Y, Nakamichi, Y, Takeda, S, Sakai, S, Takahashi, F, Saito, H, Yasuda, H, Udagawa, N, Suda, T, Takahashi, N (2012) Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J. Bone Miner. Res. 27: pp. 461

  60. Lau, KH, Baylink, DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif. Tissue Int. 65: pp. 295

  61. O’Donnell, S, Moher, D, Thomas, K, Hanley, DA, Cranney, A (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J. Bone Miner. Metab. 26: pp. 531

  62. Brandi, ML, Minisola, S ( 2013 ) Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent. Curr. Med. Res. Opin. 29: pp. 1565

  63. Peppone, LJ, Hebl, S, Purnell, JQ, Reid, ME, Rosier, RN, Mustian, KM, Palesh, OG, Huston, AJ, Ling, MN, Morrow, GR (2010) The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos. Int. 21: pp. 1133

  64. Eisman, JA, Bouillon, R ( 2014 ) Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. Bonekey Rep. 3: pp. 499

  65. Ovesen, L, Brot, C, Jakobsen, J (2003) Food contents and biological activity of 25-hydroxyvitamin D: a vitamin D metabolite to be reckoned with?. Ann. Nutr. Metab. 47: pp. 107

  66. Smith, JE, Goodman, DS (1971) The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J. Clin. Invest. 50: pp. 2159

  67. Stamp, TC, Round, JM, Haddad, JG (1973) Effect of oral vitamin D, 25-hydroxycholecalciferol (25-HCC) and whole-body ultra-violet irradiation on plasma 25-HCC levels in man. Clin. Sci. 44: pp. 3P

  68. Stamp, TC (1974) Intestinal absorption of 25-hydroxycholecalciferol. Lancet 2: pp. 121

  69. Haddad, JG, Stamp, TC (1974) Circulating 25-hydroxyvitamin D in man. Am. J. Med. 57: pp. 57

  70. Haddad, JG, Rojanasathit, S (1976) Acute administration of 25-hydroxycholecalciferol in man. J. Clin. Endocrinol. Metab. 42: pp. 284

  71. Jones, KS, Schoenmakers, I, Bluck, LJ, Ding, S, Prentice, A (2012) Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults. Br. J. Nutr. 107: pp. 1128

  72. Stamp, TC, Haddad, JG, Twigg, CA (1977) Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D. Lancet 1: pp. 1341

  73. Hollis, BW, Conrad, HR, Hibbs, JW (1977) Changes in plasma 25-hydroxycholecalciferol and selected blood parameters after injection of massive doses of cholecalciferol or 25-hydroxycholecalciferol in non-lactating dairy cows. J. Nutr. 107: pp. 606

  74. Barger-Lux, MJ, Heaney, RP, Dowell, S, Chen, TC, Holick, MF (1998) Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos. Int. 8: pp. 222

  75. Jetter, A, Egli, A, Dawson-Hughes, B, Staehelin, HB, Stoecklin, E, Goessl, R, Henschkowski, J, Bischoff-Ferrari, HA ( 2014 ) Pharmacokinetics of oral vitamin D(3) and calcifediol. Bone 59: pp. 14

  76. Cashman, KD, Seamans, KM, Lucey, AJ, Stöcklin, E, Weber, P, Kiely, M, Hill, TR (2012) Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am. J. Clin. Nutr. 95: pp. 1350

  77. Chou, SH, Chung, TK, Yu, B (2009) Effects of supplemental 25-hydroxycholecalciferol on growth performance, small intestinal morphology, and immune response of broiler chickens. Poult. Sci. 88: pp. 2333

  78. Lauridsen, C, Halekoh, U, Larsen, T, Jensen, SK (2010) Reproductive performance and bone status markers of gilts and lactating sows supplemented with two different forms of vitamin D. J. Anim. Sci. 88: pp. 202

  79. Sahin, N, Balci, TA, Kucuk, O, Smith, MO, Sahin, K (2009) Effects of 25-hydroxycholecalciferol and soy isoflavones supplementation on bone mineralisation of quail. Br. Poult. Sci. 50: pp. 709

  80. Hines, EA, Coffey, JD, Starkey, CW, Chung, TK, Starkey, JD ( 2013 ) Improvement of maternal vitamin D status with 25-hydroxycholecalciferol positively impacts porcine fetal skeletal muscle development and myoblast activity. J. Anim. Sci. 91: pp. 4116

  81. Hahn, TJ, Halstead, LR, Teitelbaum, SL, Hahn, BH (1979) Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J. Clin. Invest. 64: pp. 655

  82. Francis, RM, Peacock, M, Storer, JH, Davies, AE, Brown, WB, Nordin, BE (1983) Calcium malabsorption in the elderly: the effect of treatment with oral 25-hydroxyvitamin D3. Eur. J. Clin. Invest. 13: pp. 391

  83. Russo, S, Carlucci, L, Cipriani, C, Ragno, A, Piemonte, S, Fiacco, RD, Pepe, J, Fassino, V, Arima, S, Romagnoli, E, Minisola, S (2011) Metabolic changes following 500 μg monthly administration of calcidiol: a study in normal females. Calcif. Tissue Int. 89: pp. 252

  84. Peacock, M, Liu, G, Carey, M, McClintock, R, Ambrosius, W, Hui, S, Johnston, CC (2000) Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J. Clin. Endocrinol. Metab. 85: pp. 3011

  85. Sosa, M, Láinez, P, Arbelo, A, Navarro, MC (2000) The effect of 25-dihydroxyvitamin D on the bone mineral metabolism of elderly women with hip fracture. Rheumatology (Oxford) 39: pp. 1263

  86. Bischoff-Ferrari, HA, Dawson-Hughes, B, Stöcklin, E, Sidelnikov, E, Willett, WC, Edel, JO, Stähelin, HB, Wolfram, S, Jetter, A, Schwager, J, Henschkowski, J, Eckardstein, A, Egli, A (2012) Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J. Bone Miner. Res. 27: pp. 160

  87. Bianchi, ML, Colombo, C, Assael, BM, Dubini, A, Lombardo, M, Quattrucci, S, Bella, S, Collura, M, Messore, B, Raia, V, Poli, F, Bini, R, Albanese, CV, Rose, V, Costantini, D, Romano, G, Pustorino, E, Magazzù, G, Bertasi, S, Lucidi, V, Traverso, G, Coruzzo, A, Grzejdziak, AD ( 2013 ) Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respir. Med. 1: pp. 377

  88. Drincic, A, Fuller, E, Heaney, RP, Armas, LA ( 2013 ) 25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults. J. Clin. Endocrinol. Metab. 98: pp. 4845

  89. Petta, S, Cammà, C, Scazzone, C, Tripodo, C, Marco, V, Bono, A, Cabibi, D, Licata, G, Porcasi, R, Marchesini, G, Craxí, A (2010) Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51: pp. 1158

  90. Avioli, LV, Birge, SJ, Lee, SW (1968) Effects of prednisone on vitamin D metabolism in man. J. Clin. Endocrinol. Metab. 28: pp. 1341

  91. Carré, M, Ayigbedé, O, Miravet, L, Rasmussen, H (1974) The effect of Prednisolone upon the metabolism and action of 25-hydroxy-and 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 71: pp. 2996

  92. Hamed, SA (2011) Influences of bone and mineral metabolism in epilepsy. Expert Opin. Drug Saf. 10: pp. 265

  93. Mutair, Al (2012) A.N., Nasrat, G.H., Russell, D.W.: mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency. J. Clin. Endocrinol. Metab. 97: pp. E2022

  94. Garcia-Delgado, I, Prieto, S, Gil-Fraguas, L, Robles, E, Rufilanchas, JJ, Hawkins, F (1997) Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif. Tissue Int. 60: pp. 155

  95. Talalaj, M, Gradowska, L, Marcinowska-Suchowierska, E, Durlik, M, Gaciong, Z, Lao, M (1996) Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant. Proc. 28: pp. 3485

  96. Compston, JE, Creamer, B (1977) Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection. Gut 18: pp. 171

  97. Batchelor, AJ, Watson, G, Compston, JE (1982) Changes in plasma half-life and clearance of 3H-25-hydroxyvitamin D3 in patients with intestinal malabsorption. Gut 23: pp. 1068

  98. Davies, M, Mawer, EB, Krawitt, EL (1980) Comparative absorption of vitamin D3 and 25-hydroxyvitamin D3 in intestinal disease. Gut 21: pp. 287

  99. Michaud, J, Naud, J, Ouimet, D, Demers, C, Petit, JL, Leblond, FA, Bonnardeaux, A, Gascon-Barré, M, Pichette, V (2010) Reduced hepatic synthesis of calcidiol in uremia. J. Am. Soc. Nephrol. 21: pp. 1488

  100. Jean, G, Terrat, JC, Vanel, T, Hurot, JM, Lorriaux, C, Mayor, B, Chazot, C (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol. Dial. Transplant. 23: pp. 3670

  101. Schmidt-Gayk, H, Grawunder, C, Tschöpe, W, Schmitt, W, Ritz, E, Pietsch, V, Andrassay, K, Bouillon, R (1977) 25-hydroxy-vitamin-D in nephrotic syndrome. Lancet 2: pp. 105

  102. Boer, IH, Sachs, MC, Cleary, PA, Hoofnagle, AN, Lachin, JM, Molitch, ME, Steffes, MW, Sun, W, Zinman, B, Brunzell, JD (2012) Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J. Clin. Endocrinol. Metab. 97: pp. 4780

  103. Foresta, C, Strapazzon, G, Toni, L, Perilli, L, Mambro, A, Muciaccia, B, Sartori, L, Selice, R (2011) Bone mineral density and testicular failure: evidence for a role of vitamin D 25-hydroxylase in human testis. J. Clin. Endocrinol. Metab. 96: pp. E646

  104. Caniggia, A, Nuti, R, Lore, F, Martini, G, Turchetti, V, Righi, G (1990) Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism. 39: pp. 43

  105. Caniggia, A, Nuti, R, Loré, F, Martini, G, Frediani, B, Giovani, S (1993) Total body absorptiometry in postmenopausal osteoporosis patients treated with 1 alpha-hydroxylated vitamin D metabolites. Osteoporos. Int. 3: pp. 181

  106. Tilyard, MW, Spears, GF, Thomson, J, Dovey, S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N. Engl. J. Med. 326: pp. 357

  107. Sambrook, P, Henderson, NK, Keogh, A, MacDonald, P, Glanville, A, Spratt, P, Bergin, P, Ebeling, P, Eisman, J (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. J. Bone Miner. Res. 15: pp. 1818

  108. Gallagher, JC, Fowler, SE, Detter, JR, Sherman, SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J. Clin. Endocrinol. Metab. 86: pp. 3618

  109. Gallagher, JC, Rapuri, PB, Smith, LM (2007) An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment. J. Clin. Endocrinol. Metab. 92: pp. 51

  110. Rhee, Y, Kang, M, Min, Y, Byun, D, Chung, Y, Ahn, C, Baek, K, Mok, J, Kim, D, Kim, D, Kim, H, Kim, Y, Myoung, S, Kim, D, Lim, SK (2006) Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos. Int. 17: pp. 1801

  111. Suh, HW, Kim, HO, Kim, YS, Sunwoo, S, Lee, JA, Lee, HR, Kim, B, Kim, DH, Choi, YS, Cheong, YS, Yum, K, Yang, YJ, Yu, BY, Cho, CH, Park, SB, Shin, DH (2012) Korea Post-Marketing Surveillance Research Group. The efficacy and safety of a combined alendronate and calcitriol agent (maxmarvil): a postmarketing surveillance study in korean postmenopausal women with osteoporosis. Korean. J Fam. Med. 33: pp. 346

  112. Trump, DL, Potter, DM, Muindi, J, Brufsky, A, Johnson, CS (2006) Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106: pp. 2136

  113. Orimo, H, Schacht, E (2005) The D-hormone analog alfacalcidol: the pioneer beyond the horizon of osteoporosis treatment. J. Rheumatol. Suppl. 76: pp. 4

  114. Francis, RM, Boyle, IT, Moniz, C, Sutcliffe, AM, Davis, BS, Beastall, GH, Cowan, RA, Downes, N (1996) A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos. Int. 6: pp. 284

  115. Nuti, R, Bianchi, G, Brandi, ML, Caudarella, R, D’Erasmo, E, Fiore, C, Isaia, GC, Luisetto, G, Muratore, M, Oriente, P, Ortolani, S (2006) Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol. Int. 26: pp. 445

  116. Reginster, JY, Kuntz, D, Verdickt, W, Wouters, M, Guillevin, L, Menkès, CJ, Nielsen, K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos. Int. 9: pp. 75

  117. Ringe, JD, Dorst, A, Faber, H, Schacht, E, Rahlfs, VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol. Int. 24: pp. 63

  118. Dukas, L, Bischoff, HA, Lindpaintner, LS, Schacht, E, Birkner-Binder, D, Damm, TN, Thalmann, B, Stähelin, HB (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J. Am. Geriatr. Soc. 52: pp. 230

  119. Dukas, L, Schacht, E, Mazor, Z, Stähelin, HB (2005) Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos. Int. 16: pp. 198

  120. Ringe, JD, Farahmand, P, Schacht, E ( 2013 ) Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol. Int. 33: pp. 637

  121. Gallagher, JC (2004) The effects of calcitriol on falls and fractures and physical performance tests. J. Steroid Biochem. Mol. Biol. 89–90: pp. 497

  122. Ringe, JD, Farahmand, P, Schacht, E, Rozehnal, A (2007) Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol. Int. 27: pp. 425

  123. Matsumoto, T, Miki, T, Hagino, H, Sugimoto, T, Okamoto, S, Hirota, T, Tanigawara, Y, Hayashi, Y, Fukunaga, M, Shiraki, M, Nakamura, T (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 90: pp. 5031

  124. Matsumoto, T, Kubodera, N (2007) ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J. Steroid Biochem. Mol. Biol. 103: pp. 584

  125. Matsumoto, T, Ito, M, Hayashi, Y, Hirota, T, Tanigawara, Y, Sone, T, Fukunaga, M, Shiraki, M, Nakamura, T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures–a randomized, active comparator, double-blind study. Bone 49: pp. 605

  126. Hagino, H, Takano, T, Fukunaga, M, Shiraki, M, Nakamura, T, Matsumoto, T ( 2013 ) Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J. Bone Miner. Metab. 31: pp. 183

  127. Caraceni, MP, Gandolini, GC, Campanini, F, Iannetta, MA, Ortolani, S (1990) Vitamin D metabolites in spasmophilia. Biomed. Pharmacother. 44: pp. 479

  128. Avenell, A, Mak, JC, O’Connell, D ( 2014 ) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst. Rev. 4: pp. CD000227

Tags: Osteoporosis